Is Frankincense Actually Good for Joint Pain?

Frankincense extract shows genuine promise for joint pain, particularly osteoarthritis of the knee, with multiple randomized controlled trials reporting meaningful reductions in pain, stiffness, and physical limitation compared to placebo. The active compounds, called boswellic acids, dampen inflammation through pathways that differ from those targeted by conventional anti-inflammatory drugs, which partly explains why the resin has attracted serious pharmacological attention rather than remaining a folk remedy curiosity. The evidence is encouraging enough to take seriously, but the picture is messier than supplement marketing suggests, with real questions about which products deliver enough of the right compounds into your bloodstream to matter.

What Boswellic Acids Do Inside an Inflamed Joint

Frankincense resin comes from trees in the genus Boswellia, and the compounds researchers care about are a family of molecules called boswellic acids. Among these, one abbreviated AKBA is considered the most pharmacologically active.¹ These acids work on inflammation through at least two key mechanisms. First, they inhibit an enzyme called 5-lipoxygenase, which your body uses to produce leukotrienes, a class of molecules that drive inflammatory swelling and pain. Lab studies show that boswellic acids directly block this enzyme and suppress leukotriene production in immune cells.² Second, they dial down a broader cascade of inflammatory signaling by blocking NF-κB activation and reducing production of pro-inflammatory cytokines like TNF-α, IL-1, and IL-6.³

This matters because standard over-the-counter anti-inflammatories like ibuprofen target a different enzyme, cyclooxygenase (COX). Boswellic acids hit the 5-lipoxygenase pathway instead, which means they reduce a different branch of the inflammatory response. Some researchers have found that frankincense preparations don’t just suppress pro-inflammatory molecules but also boost the production of inflammation-resolving compounds called specialized pro-resolving mediators, suggesting the extract may help actively wind down inflammation rather than simply blocking one piece of it.⁴

There is an important caveat embedded in the early pharmacology work, though. One of the foundational studies on 5-lipoxygenase inhibition noted that while boswellic acids are effective inhibitors in lab-dish experiments, “the pharmacological relevance of such interference in vivo seems questionable.”² In other words, showing that a compound blocks an enzyme in a test tube is not the same as showing it reaches inflamed joints at high enough concentrations when you swallow a capsule. This gap between lab-dish potency and real-world effect runs through the entire frankincense story.

What Happens to Cartilage

Beyond dampening pain signals, there is lab evidence that frankincense may help protect the structural tissue inside joints. In osteoarthritis, enzymes called matrix metalloproteinases chew through collagen, gradually degrading the cartilage that cushions bone. A study on one frankincense species, Boswellia frereana, found that its extract reduced collagen breakdown in cartilage tissue stimulated with inflammatory molecules. It suppressed the enzymes responsible for cartilage destruction and lowered the production of prostaglandin E2 and nitric oxide, both of which fuel joint inflammation.⁵ This is still a lab finding, not proof that taking frankincense will preserve your cartilage over years. But it suggests the compounds may do more than mask symptoms.

The Clinical Trial Evidence for Knee Osteoarthritis

Several randomized, double-blind, placebo-controlled trials have tested Boswellia extracts in people with knee osteoarthritis, and the results are consistently positive, though the trials are all relatively small. One study using a proprietary Boswellia serrata extract called Aflapin found that participants experienced a roughly 45% reduction in pain scores, a 66% drop in stiffness, and a 48% improvement in overall joint function compared to baseline, all within 30 days.⁶ Pain scores in that trial began improving within five days of starting the supplement.

Another trial tested a high-potency, water-dispersible Boswellia extract and found statistically significant reductions in pain, stiffness, and overall symptom scores compared to placebo. That study also measured high-sensitivity C-reactive protein, a blood marker of systemic inflammation, and found it dropped in the treatment group. Pain and stiffness improvements appeared within seven days.⁷ A separate trial using a topical frankincense oil preparation applied directly to the knee also found significant improvement over placebo for all measured outcomes.⁸

These trials are encouraging, but they share limitations. Most enrolled fewer than 100 participants, ran for only a few weeks to a few months, and tested proprietary formulations developed by supplement companies that often funded the research. That does not mean the results are wrong, but it does mean we are still waiting for larger, longer, and more independently funded trials to confirm how big and how durable the benefit really is.

Oral Versus Topical Use

You will find frankincense sold both as oral capsules and as topical creams, gels, and oils. Both routes have some evidence behind them, but they work differently. Oral supplements deliver boswellic acids through the bloodstream, which means they must survive digestion and absorption before reaching inflamed tissue. Topical preparations bypass digestion entirely and deliver active compounds directly to the skin over the affected area.

Research on topical frankincense suggests that the volatile compounds in the essential oil fraction, including α-pinene, linalool, and 1-octanol, contribute their own anti-inflammatory and pain-relieving effects by inhibiting COX-2 expression locally. One animal study found that the oily extract of frankincense applied to the skin reduced swelling and pain more quickly than a water-based extract.⁹ The randomized trial of a topical oily solution on human knee OA also showed benefit over placebo.⁸ For superficial joints like knees and fingers, topical application may deliver useful concentrations where they are needed while avoiding the bioavailability problems that plague oral supplements. For deeper joints like hips, oral supplementation is probably the only realistic route.

The Bioavailability Problem

Boswellic acids are fat-soluble and poorly absorbed from the gut. This is arguably the biggest practical hurdle for frankincense supplements. If only a small fraction of what you swallow reaches your bloodstream, the impressive results from test-tube experiments become much harder to replicate in a living body. Researchers have been working on this for years, developing novel delivery systems to improve absorption.

One approach uses lecithin-based formulations (phytosomes) to wrap the active compounds in a form the gut absorbs more readily. A study in mice found that a soy lecithin formulation of Boswellia extract achieved plasma levels up to seven-fold higher for one key boswellic acid compared to the unformulated extract, with correspondingly higher tissue concentrations.¹⁰ Other strategies under investigation include nanoparticles, micelles, and ligand-targeted carriers.¹¹

This matters for you as a consumer because not all Boswellia supplements on the shelf are equivalent. A generic capsule of ground Boswellia resin may deliver very little active compound into your system, while a standardized, bioavailability-enhanced extract could deliver several times more. The clinical trials showing positive results all used specific proprietary formulations, not bulk resin powder. If you are going to try frankincense for joint pain, a product that specifies its boswellic acid content and uses some form of absorption enhancement is more likely to match the conditions that produced positive trial results.

Combining Frankincense with Curcumin

Several recent trials have tested Boswellia extract alongside curcumin (the active compound in turmeric), based on the idea that these two anti-inflammatory agents attack overlapping but distinct pathways and may amplify each other. The evidence for this synergy is growing. A trial comparing curcumin alone, Boswellia alone, and the combination in osteoarthritis patients found that the combination product outperformed either ingredient in isolation.¹² A more recent study tested a co-delivered Boswellia-curcumin complex using enhanced bioavailability technology in people with moderate spinal inflammation and found the combination superior to Boswellia extract alone in reducing pain and stiffness.¹³

Both curcumin and boswellic acids face similar bioavailability challenges, so the newer combination products tend to incorporate absorption-enhancing technology for both ingredients. If you already take turmeric or curcumin for joint support, adding a Boswellia product, or switching to a combination formula, may be worth considering. That said, combination supplements are usually more expensive, and the synergy has been demonstrated in only a few trials so far.

Safety, Side Effects, and Drug Interactions

Frankincense has a reassuring safety profile compared to long-term use of NSAIDs like ibuprofen or naproxen, which carry well-known risks of stomach ulcers, kidney damage, and cardiovascular events. Formal toxicity studies in animals have tested boswellic acids at very high doses without finding significant problems. One early study gave oral doses up to 2 grams per kilogram of body weight to rats and mice without any deaths, and long-term daily dosing in rats and monkeys showed no meaningful changes in blood work, organ weights, or tissue pathology.¹⁴ More recent 28-day and 90-day toxicity studies in rats have confirmed broad-spectrum safety at the doses tested, with no adverse effects on liver function, kidney markers, or blood cell counts.¹⁵¹⁶

In human clinical trials, side effects have generally been mild and comparable to placebo, mostly limited to occasional gastrointestinal discomfort. The biggest concern is not the supplement’s direct toxicity but its potential to interact with medications. Frankincense extracts from multiple Boswellia species have been identified as non-selective inhibitors of major cytochrome P450 enzymes, the liver enzymes that metabolize a wide range of prescription drugs. The affected enzymes include several of the most clinically important ones: CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4.¹⁷ If you take blood thinners, certain antidepressants, immunosuppressants, statins, or other drugs metabolized by these enzymes, frankincense could theoretically slow their breakdown and increase their blood levels. This has not been extensively studied in humans, but the lab evidence is strong enough that you should mention frankincense use to your prescribing doctor if you are on any regular medications.

Which Species and Products Matter

The genus Boswellia includes about two dozen species, but only a handful are widely used medicinally. Boswellia serrata is by far the most studied and the species behind most supplements on the market. Boswellia sacra (also called Boswellia carterii in some classifications) is the species traditionally associated with the aromatic frankincense used in religious ceremonies and has a long history of folk use for pain.¹⁸ Boswellia frereana is the species tested in the cartilage-protection research mentioned earlier. The Chinese pharmacopoeia has formally recognized frankincense for its ability to relieve pain and reduce swelling.¹⁹

The chemical profiles of these species differ. Not all frankincense essential oils or resins contain the same ratios of boswellic acids. When you buy a product, look for one that discloses the boswellic acid content as a percentage, ideally standardized to include AKBA. Products marketed simply as “frankincense essential oil” for aromatherapy typically contain volatile terpenes (the fragrant compounds) but little to none of the heavier boswellic acids responsible for the anti-inflammatory activity. Aromatherapy-grade frankincense oil and a Boswellia extract supplement are different products aimed at different purposes.

Evidence from Veterinary Use

One interesting line of supporting evidence comes from veterinary medicine, where Boswellia has been tested in dogs with osteoarthritis. Dogs cannot experience a placebo effect in the way humans can, which makes these studies a useful cross-check. In one trial, about 71% of dogs showed improvement within two weeks of starting a Boswellia resin supplement, with statistically significant reductions in lameness, stiffness, and pain by six weeks.²⁰ A separate study tested a combination of curcumin and boswellic acid added to a conventional joint supplement in dogs and found that the dogs receiving the combination showed greater improvement in gait measurements over the course of the trial.²¹ These results do not prove efficacy in humans, but they reinforce the idea that something pharmacologically real is happening beyond expectation or belief.

The Sustainability Question Behind the Supply

If frankincense supplements continue to gain popularity, the ecological backstory becomes relevant to anyone who cares about where their products come from. The trees that produce frankincense resin are in serious trouble. Research on Boswellia papyrifera, the main commercial source of frankincense, has documented population collapse across its range. Over 75% of studied populations lack young trees, natural regeneration has been absent for decades in many areas, and projections estimate that frankincense production will be halved within 20 years.²² The causes are not primarily harvesting itself, but a combination of cattle grazing, frequent fires, reckless tapping practices, and beetle infestations.²³

In Somaliland, which is one of the most important frankincense-producing regions, researchers have documented significant overharvesting driven by breakdown of traditional management systems. Demand and prices rose sharply between 2010 and 2017 even as tree populations declined, creating incentives for short-term exploitation. The supply chain has become increasingly complex and opaque, making it difficult for international buyers to verify that their resin was harvested sustainably.²⁴ Population models suggest that without intensive management, including full sapling recruitment and major reductions in adult tree mortality, both populations and frankincense yields will continue declining steeply.²³ For now, few supplement brands disclose anything about the sustainability of their raw material sourcing. As demand grows, this is a gap worth paying attention to.